| Trial ID: | L4183 |
| Source ID: | NCT00574834
|
| Associated Drug: |
Ramipril
|
| Title: |
Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00574834/results
|
| Conditions: |
Metabolic Syndrome
|
| Interventions: |
DRUG: Ramipril|DRUG: HCTZ-hydrochlorothiazide|DRUG: Ramipril+HCTZ
|
| Outcome Measures: |
Primary: Changes in Insulin Sensitivity, Measures of change in endogenous glucose production from baseline to final 30 minutes of clamp studies after 6 months of treatment., 6 months |
|
| Sponsor/Collaborators: |
Sponsor: University of Maryland, Baltimore | Collaborators: King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
EARLY_PHASE1
|
| Enrollment: |
17
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2007-03
|
| Completion Date: |
2014-08
|
| Results First Posted: |
2016-01-15
|
| Last Update Posted: |
2019-09-12
|
| Locations: |
University of Maryland, Baltimore, Baltimore, Maryland, 21201, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00574834
|
